AU2017315265C1 - Method for treating pruritus and/or itch - Google Patents

Method for treating pruritus and/or itch Download PDF

Info

Publication number
AU2017315265C1
AU2017315265C1 AU2017315265A AU2017315265A AU2017315265C1 AU 2017315265 C1 AU2017315265 C1 AU 2017315265C1 AU 2017315265 A AU2017315265 A AU 2017315265A AU 2017315265 A AU2017315265 A AU 2017315265A AU 2017315265 C1 AU2017315265 C1 AU 2017315265C1
Authority
AU
Australia
Prior art keywords
ring
aryl
alkyl
pyrone
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017315265A
Other languages
English (en)
Other versions
AU2017315265A1 (en
AU2017315265B2 (en
Inventor
Moshe Laudon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of AU2017315265A1 publication Critical patent/AU2017315265A1/en
Application granted granted Critical
Publication of AU2017315265B2 publication Critical patent/AU2017315265B2/en
Publication of AU2017315265C1 publication Critical patent/AU2017315265C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017315265A 2016-08-23 2017-06-30 Method for treating pruritus and/or itch Active AU2017315265C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378435P 2016-08-23 2016-08-23
US62/378,435 2016-08-23
PCT/IB2017/053989 WO2018037295A1 (en) 2016-08-23 2017-06-30 Method for treating pruritus and/or itch

Publications (3)

Publication Number Publication Date
AU2017315265A1 AU2017315265A1 (en) 2019-02-28
AU2017315265B2 AU2017315265B2 (en) 2021-03-11
AU2017315265C1 true AU2017315265C1 (en) 2021-06-10

Family

ID=59416750

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017315265A Active AU2017315265C1 (en) 2016-08-23 2017-06-30 Method for treating pruritus and/or itch

Country Status (11)

Country Link
US (1) US20190175554A1 (enExample)
EP (1) EP3503884B1 (enExample)
JP (1) JP6910424B2 (enExample)
KR (1) KR20190040298A (enExample)
CN (1) CN109843286A (enExample)
AU (1) AU2017315265C1 (enExample)
CA (1) CA3033534A1 (enExample)
MX (1) MX381311B (enExample)
SG (1) SG11201901449XA (enExample)
TW (1) TW201808269A (enExample)
WO (1) WO2018037295A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7048051B2 (ja) * 2018-07-11 2022-04-05 正徳 染井 痒みを軽減するアトピー性皮膚炎治療剤
WO2021151059A1 (en) * 2020-01-24 2021-07-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Compounds and methods for treating or reducing pruritus
BR112022017801A2 (pt) * 2020-03-11 2022-10-25 Nocion Therapeutics Inc Bloqueadores de canais de íons carregados e métodos para uso
CA3237199A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
WO2024229352A2 (en) * 2023-05-04 2024-11-07 Caamtech, Inc. Tryptamine derivatives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834317A1 (en) * 1995-06-14 1998-04-08 Institute of Immunology Co., Ltd. Ameliorant for pruritus cutaneous accompanying renal failure
WO2007093880A2 (en) * 2006-02-15 2007-08-23 Neurim Pharmaceuticals (1991) Ltd. Novel pyrone-indole derivatives and process for their preparation
US20130324583A1 (en) * 2006-02-15 2013-12-05 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
WO2014144545A2 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
DE69715049T2 (de) * 1996-02-07 2003-04-03 Kissei Pharmaceutical Co., Ltd. Tranilast enthaltendes externum und verfahren zu dessen herstellung
KR19990022058A (ko) * 1996-03-27 1999-03-25 마에다 가쯔노스께 케톤유도체 및 그 의약용도
JP2000327570A (ja) * 1999-05-24 2000-11-28 Nof Corp 皮膚外用剤
US6552073B1 (en) * 2002-03-01 2003-04-22 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases
JP5513705B2 (ja) * 2006-03-29 2014-06-04 小林製薬株式会社 知覚過敏型肌掻痒感改善剤
WO2008036979A2 (en) * 2006-09-22 2008-03-27 Guilford F Timothy Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes
KR101359078B1 (ko) * 2011-03-08 2014-02-05 이홍식 자주색 산삼배양근의 제조방법
CN105492430B (zh) * 2013-03-15 2017-10-10 基因泰克公司 取代的苯并噁唑及其使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834317A1 (en) * 1995-06-14 1998-04-08 Institute of Immunology Co., Ltd. Ameliorant for pruritus cutaneous accompanying renal failure
WO2007093880A2 (en) * 2006-02-15 2007-08-23 Neurim Pharmaceuticals (1991) Ltd. Novel pyrone-indole derivatives and process for their preparation
US20130324583A1 (en) * 2006-02-15 2013-12-05 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
WO2014144545A2 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof

Also Published As

Publication number Publication date
EP3503884A1 (en) 2019-07-03
MX381311B (es) 2025-03-12
MX2019002149A (es) 2019-09-18
TW201808269A (zh) 2018-03-16
KR20190040298A (ko) 2019-04-17
WO2018037295A1 (en) 2018-03-01
SG11201901449XA (en) 2019-03-28
CN109843286A (zh) 2019-06-04
CA3033534A1 (en) 2018-03-01
JP6910424B2 (ja) 2021-07-28
AU2017315265A1 (en) 2019-02-28
JP2019524797A (ja) 2019-09-05
EP3503884B1 (en) 2021-07-21
AU2017315265B2 (en) 2021-03-11
US20190175554A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
AU2017315265B2 (en) Method for treating pruritus and/or itch
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
EP0910565A1 (en) Amide derivatives as selective neuropeptide y receptor antagonists
KR100469029B1 (ko) 세로토닌재흡수억제제의위장효과를극복하기위한5ht4수용체길항제의용도
HUP0002956A2 (hu) 4-Amino-pirrolo[3,2-d]pirimidin-származékok alkalmazása Y neuropeptid fölösleg okozta megbetegedések gyógyítására szolgáló gyógyszerkészítmények előállítására
EA012502B1 (ru) Соединения, специфичные к меланокортиновым рецепторам
JP4897683B2 (ja) チエノピリジノン化合物及び治療方法
JP7737721B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
US20140243350A1 (en) Use of serotonin receptor agonists for treatment of movement disorders
CN111989313A (zh) A2a和/或a2b受体拮抗剂
KR20080093453A (ko) 4-아실아미노피리딘 유도체 매개된 신경조직발생
US20140221385A1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
JP2014514259A (ja) 疼痛および他の障害の処置のための化合物および方法
US20140128398A1 (en) Compounds, compositions and methods for treating oxidative dna damage disorders
US20210401838A1 (en) Identification of agents displaying functional activation of dopamine d2 and d4 receptors
CA2814828C (en) Method of treatment for mental disorders
CN112592354B (zh) 一种异噁唑并嘧啶类杂环化合物的制备方法
JP7265526B2 (ja) てんかん治療剤
JP2007506784A (ja) 双極性障害およびその他の認知障害の治療における、ケレリトリン、その類似体およびそれらの使用
CN1930123B (zh) 用于预防或治疗伴有神经障碍的膀胱过度活动症的医药组合物
JP2021525269A (ja) 疼痛処置のための化合物、それを含む組成物及びそれを使用する方法
HK40009658A (en) Method for treating pruritus and/or itch
WO2025189066A1 (en) Modulators of g protein-coupled receptor 55 (gpr55)
US20210267960A1 (en) Methods of treatment of inflammatory cytokine-related arthritic disorders
BR112019010127A2 (pt) agentes psicotrópicos e usos dos mesmos

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 FEB 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 23 FEB 2021

FGA Letters patent sealed or granted (standard patent)